Nationwide dispensing of cardioprotective medications during the first year following acute coronary syndrome (ANZACS-QI 56)
Open Access
PDF Download
Unless contraindicated, the current guidelines for secondary prevention following acute coronary syndrome (ACS) recommend a statin for all patients. Patients should also receive combination antithrombotic therapy usually a combination of aspirin and a PY212 inhibitor antiplatelet agent. But, for patients with atrial fibrillation, an oral anticoagulant may be added or substituted for an antiplatelet agent. For most patients, a beta-blocker and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) are also indicated. These medications have been shown to reduce mortality and improve outcomes after ACS.1–8